Thalidomide benefits patients with refractory multiple myeloma

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1342, 2002-01, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thalidomide in multiple myeloma

By García-Sanz Ramón

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 2, 2006-02 ,pp. : 195-213

Informa Healthcare

Access to resources Recommend Favorite

Thalidomide in Multiple Myeloma

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 6, 2006-12 ,pp. : 431-440

Bentham Science Publishers

Access to resources Recommend Favorite

High-dose tamoxifen is not a feasible option in patients with relapsed or refractory multiple myeloma

Inpharma, Vol. 1, Iss. 1439, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients

By Barbee Meagan S. Nooka Ajay Kaufman Jonathan L. Kim Sungjin Chen Zhengjia Heffner Leonard T. Lonial Sagar Harvey R. Donald

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 853-862

Blackwell Publishing

Access to resources Recommend Favorite

Thalidomide improves response rate, survival in multiple myeloma

Inpharma, Vol. 1, Iss. 1569, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite